Agatha Welcomes Ken Lownie To Lead North American Operations

KenLownie

Boston, USA; Tokyo, Japan; Lyon, France, January 22, 2020. Agatha, a provider of business applications for life sciences companies, announced today that Ken Lownie has joined the company as its head of North American Operations. Lownie is an enterprise software executive with previous experience navigating companies through periods of rapid growth. He will be responsible for sales, customer success, and operations in North America.

Agatha is experiencing strong growth in Japan, the EU, and the US. It recently received an investment of an additional $4 million; among the investors is Salesforce Ventures. The funds will be used to drive customer success worldwide, including the US and Canada.

According to Guillaume Gerard, Agatha’s COO, the US market is a key focus area for the company.

“We have a solid base of customers in the US. We have proven that our position in the market as a provider of ready-to-use, cloud-based applications is very attractive to life sciences companies, and we expect that North America will rapidly become our biggest market”.

Lownie’s mission is to leverage Agatha’s ability to provide cloud-based, ready-to-use applications to grow the US business.

“Agatha is clearly poised for a period of rapid growth. When it comes to tasks like managing clinical trial TMF documents, SOPs and quality documents, customers are looking for ready-to-use applications, not platforms. They are done with complex, expensive systems that require a lot of time, money and effort to configure and customize,” said Ken Lownie.

More Information


About Agatha, Inc.

Agatha, Inc. is a leading strategic software solutions provider to the healthcare and life sciences industry. Agatha is dedicated to helping the world’s Hospitals, biotechnology, pharmaceutical, contract research organizations, and medical device firms optimize the management of their Quality, Regulatory and Clinical documentation and processes.

Press Inquiries Contact:
Barb Mosher Zinck
email: Barb.mzinck@agathalife.com
phone: 1 978.618.2363
https://en.agathalife.com

MABLINK BIOSCIENCE adopte les solutions logicielles Agatha

Mablink partnership

Lyon, France, Boston, US, Tokyo, Japon, 10 janvier 2020 – Agatha Inc., un leader mondial des solutions de gestion de la qualité et du contenu pour les sciences de la vie, annonce aujourd’hui que Mablink Bioscience, une société de biotechnologie basée en France spécialisée en immuno-oncologie, adopte la solution d’Agatha.

“Mablink a pour objectif de démocratiser le développement d’ADC de 3e génération, qui sont une nouvelle classe de médicament contre le cancer. “En nous équipant de la solution de gestion documentaire développée par Agatha Life, nous voulons nous donner la possibilité de scaler très vite et de pouvoir gérer professionnellement les demandes de nos clients. Cette volonté de structurer dès le départ notre activité fait partie de la stratégie de développement de Mablink”, indique Jean-Guillaume Lafay, CEO de Mablink

L’approche de Mablink repose sur son expertise en chimie, pharmacologie et immuno-oncologie, ce qui lui permet de couvrir l’ensemble de la chaîne de valeur de la conception d’ADC de 3e génération. Sur le plan international, l’attente est forte de la part des laboratoires pharmaceutiques et des sociétés de biotechnologies.

Selon Guillaume Gerard, Directeur Executif d’Agatha, Inc., les innovateurs comme Mablink doivent disposer de solutions rapides à déployer et faciles à utiliser. “Mablink et Agatha partagent un engagement en faveur de la vitesse de l’innovation, garantissant que les nouvelles avancées médicales soient disponibles pour les patients dès que possible et en toute sécurité,” a déclaré Guillaume. “Nous sommes impatients d’être un partenaire de Mablink dans la lutte contre le cancer.”

À propos de Mablink

Mablink Bioscience est une société de biotechnologie française fondée en 2018, spécialisée dans le développement d’une nouvelle classe de médicament contre le cancer, les anticorps thérapeutiques conjugués à des molécules-médicaments (appelés ADC – Antibody Drug Conjugate). Mablink capitalise sur son expertise en chimie, pharmacologie et immuno-oncologie et sur sa plateforme technologique brevetée pour concevoir des ADC de 3e génération ayant un index thérapeutique amélioré. La plateforme technologique de Mablink est universelle et s’adapte à tout type d’anticorps thérapeutiques et tout type de molécule-médicament. Elle permet de concevoir des ADC de 3e génération, hautement chargés en molécules-médicaments tout en conservant d’excellentes propriétés pharmacologiques, afin d’augmenter l’efficacité des traitements ciblés dans les cancers avancés.

www.mablink.com

À propos d’Agatha, Inc.

Agatha, Inc. est l’un des principaux fournisseurs de solutions logicielles stratégiques pour l’industrie des soins de santé et des sciences de la vie. Agatha se consacre à aider les hôpitaux, les sociétés des biotechnologies, les laboratoires pharmaceutiques, les organisations de recherche contractuelle et les sociétés de dispositifs médicaux du monde entier à optimiser la gestion de leur documentation et de leurs processus de qualité, réglementaires et cliniques.

Les solutions Agatha sont disponibles immédiatement, sont conformes aux réglementations applicables (telles que la FDA 21 CFR partie 11 et sont conçues pour une adoption rapide et une mise à l’échelle efficace. Les clients d’Agatha sont en mesure de réduire immédiatement leur risque de conformité et d’augmenter leur productivité. Ils réduisent le temps passé à gérer en moyenne 80% de leur documentation clinique, qualité et réglementaire Agatha est le partenaire de confiance de plus de 200 hôpitaux, centres de recherche, CRO, laboratoires pharmaceutiques et sociétés de dispositifs médicaux dans le monde.

Company Name: Agatha Inc.
Representative Director: Chiemi Kamakura
Office: 2F FtF Bldg, 1-2 Hakozaki-cho, Nihombashi, Chuo-ku, Tokyo 103-0015 Japan
Date of incorporation: October 2, 2015
Amount of capital: 535 million JPY (including legal capital surplus)
URL: https://www.agathalife.com

Contact:
Yasuyo Susukida
TEL:+81-50-3177-5299
Email: info@agathalife.com
https://en.agathalife.com

MABLINK BIOSCIENCE Adopts Agatha Software Solutions

Mablink partnership

Tokyo, Japan; Lyon, France; Boston, USA, January 10, 2020 – Agatha Inc., a global leader in quality and content management solutions for life sciences, today announced that Mablink Bioscience, a French-based biotech company specialized in immuno-oncology, is adopting Agatha’s solution.

Mablink aims to democratize the development of 3rd generation Antibody-Drug Conjugates (ADCs), which is a new class of cancer drugs. Mablink’s approach is rooted in its expertise in chemistry, pharmacology, and immuno-oncology in order to develop a hydrophilic easy-to-implement platform for next-generation ADCs.

“By equipping our company with the solution developed by Agatha, we want to give ourselves the possibility to scale swiftly and to be able to professionally manage the requests of our customers and partners.  The willingness to structure our processes with scalable solutions like Agatha’s, from the beginning, is part of our strategy,” said Jean-Guillaume Lafay, CEO of Mablink.

According to Guillaume Gerard, Chief Operating Officer of Agatha, Inc., innovators like Mablink need to have solutions that are fast to deploy and easy to use, so they can adopt them quickly and scale their use rapidly.

“Mablink and Agatha share a commitment to speed and innovation, ensuring that new medical advances are available to patients as soon as safely possible,” said Guillaume. “We look forward to being a partner to Mablink in their fight against cancer.”

About Mablink

Mablink Bioscience is a French-based biotechnology company founded in 2018, specialized in the development of a new class of cancer drug, called Antibody Drug Conjugate (ADC). Mablink leverages its expertise in chemistry, pharmacology, and immuno-oncology and its patented technological platform to design 3rd generation ADCs that are less toxic, more efficient and easy to manufacture. Mablink’s technological platform is universal and adapts to all types of drug-molecule. Moreover, it makes it possible to design 3rd generation ADCs that are highly loaded with drug molecules while retaining excellent pharmacological properties, in order to increase the effectiveness of targeted therapies in advanced cancers.

mablink.com

About Agatha, Inc.

Agatha, Inc. is a leading strategic software solutions provider to the health care and life sciences industry. Agatha is dedicated to helping the world’s Hospitals, biotechnology, pharmaceutical, contract research organizations, and medical device firms optimize the management of their Quality, Regulatory and Clinical documentation and processes.

Agatha solutions are available immediately, are compliant with applicable regulations (such as FDA 21 CFR part 11 and are designed for rapid adoption and effective scaling. Agatha’s clients are able to immediately decrease their compliance risk and increase their productivity; they reduce the time spent to manage their clinical, quality and regulatory documentation by 80% on average. Agatha is the trusted partner of more than 200 hospitals, research centers, CROs, pharmaceutical companies and medical device companies worldwide.

 

Company Name: Agatha Inc.
Representative Director: Chiemi Kamakura
Office: 2F FtF Bldg, 1-2 Hakozaki-cho, Nihombashi, Chuo-ku, Tokyo 103-0015 Japan
Date of incorporation: October 2, 2015
Amount of capital: 535 million JPY (including legal capital surplus)
URL: https://www.agathalife.com

US Contact:
Ken Lownie
email: ken.lownie@agathalife.com
phone: 1 978.618.2363
https://en.agathalife.com